Trials / Completed
CompletedNCT01165554
Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels
A Principal Open-Label Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Amyloid Levels Determined Post-Mortem
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- GE Healthcare · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
To determine the level of association between quantitative regional estimates of brain uptake of \[18F\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F] Flutemetamol | Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection. |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2010-07-20
- Last updated
- 2013-12-04
- Results posted
- 2013-12-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01165554. Inclusion in this directory is not an endorsement.